IL117592A0 - N-substituted sulfonamidobenzene compounds - Google Patents
N-substituted sulfonamidobenzene compoundsInfo
- Publication number
- IL117592A0 IL117592A0 IL11759296A IL11759296A IL117592A0 IL 117592 A0 IL117592 A0 IL 117592A0 IL 11759296 A IL11759296 A IL 11759296A IL 11759296 A IL11759296 A IL 11759296A IL 117592 A0 IL117592 A0 IL 117592A0
- Authority
- IL
- Israel
- Prior art keywords
- alkyl
- mono
- substd
- halogen
- opt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
3-Hydroxy-1-indolinyl sulphones of formula (I) and their salts are new: In (I), R1 = halogen, 1-4C alkyl, OH, 1-4C alkoxy, benzyloxy, CN, CF3, NO2 or NH2; R2 = 1-6C alkyl; 3-7C cycloalkyl,; 5-7C cycloalkenyl; phenyl opt. substd. by 1-4C alkyl, 1-4C alkoxy, halogen, CF3 and/or NH2; or nitrophenyl opt. substd. by CF3, 1-4C alkyl or halogen; R5 = 1-4C alkyl; 1- or 2-naphthyl;5-dimethylamino-1-naphthyl; phenyl opt. substd. by halogen, CF3, NH2, mono- or di (1-4C alkyl) amino, OH, 1-4C alkoxy, 2-4C alkenyloxy, 1-4C alkylthio, CF3, benzyloxy, CN, COOH, 2-5C alkoxycarbonyl, CONH2, mono- or di (1-4C alkyl)carbamoyl or 1-4C alkanoylamino; or nitrophenyl opt. substd. by CF3, 2-4C alkenyloxy, halogen, 1-4C alkyl, 1-4C alkoxy, 1-4C alkylthio, OCF3 or benzyloxy; R6 = 1-6C alkyl or R7; R7 = 1-R-4-piperidinyl, 1-R-3-azetidinyl or (CH2)rR'; R = H, 1-4C alkyl, benzyloxycarbonyl or 2-5C alkoxycarbonyl; R1 = pyridyl, OH, NH2, mono- or di(1-4C alkyl)amino, COOH, 2-5C alkoxycarbonyl, benzylcarbonyl, CONH2 or mono- or di(1-4C alkyl)carbamoyl; or NR6R7 = morpholino; thiomorpholino; thiazolidinyl or 2,2-dimethylthiazolidinyl opt. substd. by R8; 1-piperazinyl opt. 4-substd. by R"8; and unsatd. 5-membered monoaza ring substd. by R8; or a satd. 3- to 7-membered monoaza ring substd. by R8 and R9; R8 = R'8 or (CH2)rA1, where A1 = OH, NH2 or mono- or di(1-4C alkyl)amino; R'8 = (CH2)qA2, where A2 = COOH, 2-5C alkoxycarbonyl, benzyloxycarbonyl, CONH2, CONHOH, mono- or di(1-4C alkyl)carbamoyl, CSNH2 or mono- or di(1-4C alkyl)thiocarbamoyl; R"8 = R8' or (CH2)A3, where A3 = NH2 or mono- or di(1-4C alkyl)amino; R9 = H, halogen, (CH2rOR10), (CH2)rNR11R12, (CH2)SCONR11R'11 or N3; R10 = H, 1-4C alkyl, mesyl or tosyl; R11, R'11 and R12 = H or 1-4C alkyl, or R11 = H, and R12 = benzyloxycarbonyl or 2-5C alkoxycarbonyl; n and m = 0-2; q = 0-3; r = 0-3, but not 0 when R8 or R9 is in a position alpha to the intracyclic amidic nitrogen (SiC); s = 0 or 1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9109908A FR2679903B1 (en) | 1991-08-02 | 1991-08-02 | DERIVATIVES OF N-SULFONYL INDOLINE CARRYING AN AMIDIC FUNCTION, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME. |
IL10270396 | 1996-03-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
IL117592A0 true IL117592A0 (en) | 1996-07-23 |
Family
ID=9415909
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL11759292A IL117592A (en) | 1991-08-02 | 1992-07-31 | N-substituted sulfonamidobenzene compounds |
IL102703A IL102703A (en) | 1991-08-02 | 1992-07-31 | N-sulfonyl indoline derivatives carrying an amide functional group, their preparation and pharmaceutical compositions containing them |
IL11759296A IL117592A0 (en) | 1991-08-02 | 1996-03-21 | N-substituted sulfonamidobenzene compounds |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL11759292A IL117592A (en) | 1991-08-02 | 1992-07-31 | N-substituted sulfonamidobenzene compounds |
IL102703A IL102703A (en) | 1991-08-02 | 1992-07-31 | N-sulfonyl indoline derivatives carrying an amide functional group, their preparation and pharmaceutical compositions containing them |
Country Status (29)
Country | Link |
---|---|
EP (1) | EP0526348B1 (en) |
JP (1) | JP2633085B2 (en) |
KR (1) | KR100241583B1 (en) |
AT (1) | ATE163289T1 (en) |
AU (2) | AU658664B2 (en) |
BR (1) | BR9205336A (en) |
CA (2) | CA2093221C (en) |
CZ (1) | CZ288173B6 (en) |
DE (1) | DE69224450T2 (en) |
DK (1) | DK0526348T3 (en) |
ES (1) | ES2117038T3 (en) |
FI (2) | FI104069B1 (en) |
FR (1) | FR2679903B1 (en) |
HK (1) | HK1008741A1 (en) |
HU (2) | HUT68927A (en) |
IL (3) | IL117592A (en) |
LT (1) | LT3064B (en) |
LV (1) | LV10091B (en) |
MX (1) | MX9204487A (en) |
MY (1) | MY110517A (en) |
NO (1) | NO180047C (en) |
NZ (1) | NZ243795A (en) |
PH (1) | PH30661A (en) |
RU (1) | RU2104268C1 (en) |
SG (1) | SG47501A1 (en) |
SK (1) | SK283463B6 (en) |
UA (1) | UA27238C2 (en) |
WO (1) | WO1993003013A1 (en) |
ZA (1) | ZA925781B (en) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2665441B1 (en) * | 1990-07-31 | 1992-12-04 | Sanofi Sa | N-SULFONYL INDOLINE DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME. |
FR2708608B1 (en) * | 1993-07-30 | 1995-10-27 | Sanofi Sa | N-sulfonylbenzimidazolone derivatives, their preparation, pharmaceutical compositions containing them. |
FR2756736B1 (en) * | 1996-12-05 | 1999-03-05 | Sanofi Sa | PHARMACEUTICAL COMPOSITIONS CONTAINING N-SULFONYL INDOLINE DERIVATIVES |
US6559127B1 (en) | 1997-07-31 | 2003-05-06 | Athena Neurosciences, Inc. | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6291453B1 (en) | 1997-07-31 | 2001-09-18 | Athena Neurosciences, Inc. | 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6489300B1 (en) | 1997-07-31 | 2002-12-03 | Eugene D. Thorsett | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6583139B1 (en) | 1997-07-31 | 2003-06-24 | Eugene D. Thorsett | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6362341B1 (en) | 1997-07-31 | 2002-03-26 | Athena Neurosciences, Inc. | Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6492421B1 (en) | 1997-07-31 | 2002-12-10 | Athena Neurosciences, Inc. | Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4 |
CN1265670A (en) * | 1997-07-31 | 2000-09-06 | 伊兰药品公司 | Dipeptide and related compounds which inhibit leukocyte adhesion medicated by VLA-4 |
US7030114B1 (en) | 1997-07-31 | 2006-04-18 | Elan Pharmaceuticals, Inc. | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
JP2001512139A (en) * | 1997-07-31 | 2001-08-21 | エラン・ファーマシューティカルズ・インコーポレーテッド | Sulfonylated dipeptide compounds that inhibit leukocyte adhesion mediated by VLA-4 |
CN1265669A (en) * | 1997-07-31 | 2000-09-06 | 伊兰药品公司 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6939855B2 (en) | 1997-07-31 | 2005-09-06 | Elan Pharmaceuticals, Inc. | Anti-inflammatory compositions and method |
US6423688B1 (en) | 1997-07-31 | 2002-07-23 | Athena Neurosciences, Inc. | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 |
FR2775598A1 (en) | 1998-03-06 | 1999-09-10 | Sanofi Sa | PHARMACEUTICAL COMPOSITIONS COMPRISING A SELECTIVE ANTAGONIST OF ARGININE-VASOPRESSIN V1A RECEPTORS AND A SELECTIVE ANTAGONIST OF ARGININE-VASOPRESSIN V2 RECEPTORS |
FR2778103A1 (en) * | 1998-04-29 | 1999-11-05 | Sanofi Sa | PHARMACEUTICAL COMPOSITIONS CONTAINING IN ASSOCIATION A V1A ARGININE-VASOPRESSIN ANTAGONIST AND AN ANGIOTENSIN II AT1 RECEPTOR ANTAGONIST |
FR2786486B3 (en) * | 1998-11-16 | 2000-12-08 | Sanofi Sa | PROCESS FOR THE PREPARATION OF (2S) -1 - [(2R, 3S) -5-CHLORO-3- (2- CHLOROPHENYL) -1- (3,4-DIMETHOXY BENZENESULFONYL) -3-HYDROXY- 2,3-DIHYDRO- 1H-INDOLE-2-CARBONYL] PYRROLIDINE-2-CARBOXAMIDE, ITS SOLVATES AND / OR HYDRATES |
JP2002535316A (en) | 1999-01-22 | 2002-10-22 | エラン ファーマシューティカルズ,インコーポレイテッド | Fused-ring heteroaryl and heterocyclic compounds that inhibit leukocyte adhesion mediated by VLA-4 |
CA2359115C (en) | 1999-01-22 | 2011-06-21 | Elan Pharmaceuticals, Inc. | Acyl derivatives which treat vla-4 related disorders |
US6436904B1 (en) | 1999-01-25 | 2002-08-20 | Elan Pharmaceuticals, Inc. | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
CA2359114A1 (en) * | 1999-01-25 | 2000-07-27 | Elan Pharmaceuticals, Inc. | Compounds which inhibit leukocyte adhesion mediated by vla-4 |
US6407066B1 (en) | 1999-01-26 | 2002-06-18 | Elan Pharmaceuticals, Inc. | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 |
FR2792834A1 (en) * | 1999-04-29 | 2000-11-03 | Sanofi Sa | USE OF SR 49059, ITS PHARMACEUTICALLY ACCEPTABLE SOLVATES AND / OR HYDATES FOR THE PREPARATION OF MEDICINES USEFUL IN THE TREATMENT OR PREVENTION OF RAYNAUD PHENOMENON |
FR2805536B1 (en) * | 2000-02-25 | 2002-08-23 | Sanofi Synthelabo | NOVEL 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
FR2805992A1 (en) * | 2000-03-08 | 2001-09-14 | Sanofi Synthelabo | Oral administration of N-sulfonyl-indoline derivative to treat central nervous system, cardiovascular or gastric disorders, using polyethylene glycol, polysorbate and poloxamer as solubilizers for high bioavailability |
EP1335901B1 (en) | 2000-10-17 | 2010-04-14 | Merck Serono SA | Pharmaceutically active sulfanilide derivatives |
US7056910B2 (en) | 2000-11-28 | 2006-06-06 | Astellas Pharma Inc. | 1,4,5.6-tetrahydroimidazo[4,5-d]diazepine derivatives or salts thereof |
JP4044740B2 (en) * | 2001-05-31 | 2008-02-06 | 信越化学工業株式会社 | Resist material and pattern forming method |
JP4511184B2 (en) | 2001-12-20 | 2010-07-28 | メルク セローノ ソシエテ アノニム | Triazoles as oxytocin antagonists |
TWI281470B (en) | 2002-05-24 | 2007-05-21 | Elan Pharm Inc | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins |
MXPA04011465A (en) * | 2002-05-24 | 2005-02-14 | Millennium Pharm Inc | Ccr9 inhibitors and methods of use thereof. |
TW200307671A (en) | 2002-05-24 | 2003-12-16 | Elan Pharm Inc | Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins |
JP4528125B2 (en) * | 2002-10-11 | 2010-08-18 | アクテリオン ファーマシューティカルズ リミテッド | Sulfonylamino-acetic acid derivatives |
US6939885B2 (en) | 2002-11-18 | 2005-09-06 | Chemocentryx | Aryl sulfonamides |
US7741519B2 (en) | 2007-04-23 | 2010-06-22 | Chemocentryx, Inc. | Bis-aryl sulfonamides |
US7227035B2 (en) | 2002-11-18 | 2007-06-05 | Chemocentryx | Bis-aryl sulfonamides |
US7420055B2 (en) | 2002-11-18 | 2008-09-02 | Chemocentryx, Inc. | Aryl sulfonamides |
EP1940827B1 (en) | 2005-09-29 | 2011-03-16 | Elan Pharmaceuticals Inc. | Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4 |
ZA200803280B (en) | 2005-09-29 | 2009-11-25 | Elan Pharm Inc | Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4 |
CN101389611B (en) | 2006-02-27 | 2012-07-18 | 伊兰制药公司 | Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4 |
SG175355A1 (en) | 2009-04-27 | 2011-12-29 | Elan Pharm Inc | Pyridinone antagonists of alpha-4 integrins |
HU231206B1 (en) | 2017-12-15 | 2021-10-28 | Richter Gedeon Nyrt. | Triazolobenzazepines |
TW201938171A (en) | 2017-12-15 | 2019-10-01 | 匈牙利商羅特格登公司 | Tricyclic compounds as vasopressin V1a receptor antagonists |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3838167A (en) * | 1972-08-01 | 1974-09-24 | Lilly Co Eli | Process for preparing indoles |
US4479963A (en) * | 1981-02-17 | 1984-10-30 | Ciba-Geigy Corporation | 1-Carboxyalkanoylindoline-2-carboxylic acids |
DE3705934A1 (en) * | 1987-02-25 | 1988-09-08 | Nattermann A & Cie | Indolyl derivatives, processes for their preparation, and their use as medicaments |
FR2665441B1 (en) * | 1990-07-31 | 1992-12-04 | Sanofi Sa | N-SULFONYL INDOLINE DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME. |
-
1991
- 1991-08-02 FR FR9109908A patent/FR2679903B1/en not_active Expired - Fee Related
-
1992
- 1992-07-31 LT LTIP114A patent/LT3064B/en not_active IP Right Cessation
- 1992-07-31 CA CA002093221A patent/CA2093221C/en not_active Expired - Fee Related
- 1992-07-31 MX MX9204487A patent/MX9204487A/en not_active IP Right Cessation
- 1992-07-31 WO PCT/FR1992/000758 patent/WO1993003013A1/en active IP Right Grant
- 1992-07-31 SK SK426-93A patent/SK283463B6/en unknown
- 1992-07-31 LV LVP-92-87A patent/LV10091B/en unknown
- 1992-07-31 HU HU9300951A patent/HUT68927A/en unknown
- 1992-07-31 BR BR9205336A patent/BR9205336A/en not_active Application Discontinuation
- 1992-07-31 KR KR1019930701034A patent/KR100241583B1/en not_active IP Right Cessation
- 1992-07-31 CZ CZ1993682A patent/CZ288173B6/en not_active IP Right Cessation
- 1992-07-31 RU RU93005168A patent/RU2104268C1/en not_active IP Right Cessation
- 1992-07-31 ZA ZA925781A patent/ZA925781B/en unknown
- 1992-07-31 AU AU24758/92A patent/AU658664B2/en not_active Ceased
- 1992-07-31 CA CA002206776A patent/CA2206776C/en not_active Expired - Fee Related
- 1992-07-31 PH PH44760A patent/PH30661A/en unknown
- 1992-07-31 IL IL11759292A patent/IL117592A/en not_active IP Right Cessation
- 1992-07-31 UA UA93002340A patent/UA27238C2/en unknown
- 1992-07-31 IL IL102703A patent/IL102703A/en not_active IP Right Cessation
- 1992-07-31 JP JP5503337A patent/JP2633085B2/en not_active Expired - Fee Related
- 1992-07-31 NZ NZ243795A patent/NZ243795A/en unknown
- 1992-07-31 MY MYPI92001379A patent/MY110517A/en unknown
- 1992-08-03 EP EP92402213A patent/EP0526348B1/en not_active Expired - Lifetime
- 1992-08-03 SG SG1996002367A patent/SG47501A1/en unknown
- 1992-08-03 DE DE69224450T patent/DE69224450T2/en not_active Expired - Fee Related
- 1992-08-03 AT AT92402213T patent/ATE163289T1/en not_active IP Right Cessation
- 1992-08-03 ES ES92402213T patent/ES2117038T3/en not_active Expired - Lifetime
- 1992-08-03 DK DK92402213T patent/DK0526348T3/en active
-
1993
- 1993-04-01 NO NO931262A patent/NO180047C/en not_active IP Right Cessation
- 1993-04-01 FI FI931476A patent/FI104069B1/en not_active IP Right Cessation
-
1995
- 1995-02-03 AU AU11541/95A patent/AU691223B2/en not_active Ceased
- 1995-06-28 HU HU95P/P00474P patent/HU211884A9/en unknown
-
1996
- 1996-03-21 IL IL11759296A patent/IL117592A0/en unknown
-
1998
- 1998-01-27 FI FI980175A patent/FI107048B/en not_active IP Right Cessation
- 1998-07-03 HK HK98108861A patent/HK1008741A1/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL117592A (en) | N-substituted sulfonamidobenzene compounds | |
IL110820A0 (en) | N-substituted heterocyclic derivatives and their preparation | |
PT81748A (en) | Process for the preparation of novel oxetanones of novel intermediates which are usable in this process and of pharmaceutical compositions based on said oxetanones or based on precursors thereof | |
ES8601206A1 (en) | Aromatic substituted cyclic amidines. | |
HUP9901630A2 (en) | Novel indole-2,3-dione-3-oxime derivatives | |
NZ333926A (en) | Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use | |
DE3783657D1 (en) | PEPTIDES WITH INFLUENCE ON DIURESE AND NATURALSE, METHOD FOR THE PRODUCTION THEREOF, THE CONTAINERS THEREOF AND THEIR USE. | |
IE36710B1 (en) | Hydrazinopyridazine derivatives | |
TW197420B (en) | ||
WO2003068736A3 (en) | Mixed steroidal 1,2,4,5-tetraoxane compounds and methods of making and using thereof | |
FR2138488A1 (en) | 1-(5-indanyl)-omega-aminoalkanes - with tranquillizing activity | |
HUP9902606A2 (en) | Matrix metalloproteinase inhibitors | |
ES8404362A1 (en) | 7-Hydroxy-imino-amino-thiadiazolyl -acetamido-3-cephem derivs. | |
IL99819A0 (en) | Imidazole-2-yl derivatives of substituted bicyclic compounds,their preparation and pharmaceutical compositions containing them | |
IT1205014B (en) | New nootropic N-substd. isoxazole-5-carboxamide(s) |